Interestingly, inhibiting TLR-4 expression has been shown to improve LPS-induced IR, suggesting that targeting TLR-4 may hold therapeutic potential for managing LPS-related metabolic disorders (Kim et al., 2007; Kawamoto et al., 2008; Hussey et al., 2012). This evidence concerns the gene TLR4 and Other metabolic disease.